Initiating stiripentol before 2 years of age in patients with Dravet syndrome is safe and beneficial against status epilepticus.
Catherine ChironNicole ChemalyLaurent ChancharmeRima NabboutPublished in: Developmental medicine and child neurology (2023)
Initiating stiripentol in infants with Dravet syndrome is safe and beneficial, significantly reducing long-lasting seizures including status epilepticus, hospitalizations, and mortality in the critical first years of life.